Poster Presentations Session V
Poster Presentations Session V Wednesday, June 4, 2014
POSTERS SET-UP: 8:15 AM - 8:30 AM
POSTERS DISPLAY HOURS: 8:30 AM - 2:45 PM
POSTER AUTHOR DISCUSSION: 12:45 PM - 1:45 PM
POSTERS DISMANTLE: 2:45 PM


Poster display locations are shown below the poster codes
DIABETES/ENDOCRINE DISORDERS - Clinical Outcomes Studies
PDB1
A1
COMPARISON OF INSULIN GLARGINE VS. NPH INSULIN TREATMENT AMONG PATIENTS WITH TYPE 2 DIABETES BASED ON REVIEW OF CLINICAL TRIAL RESULTS
Lin J, Lingohr-Smith M
Novosys Health, Flemington, NJ, USA

PDB2
A2
IDENTIFYING FACTORS ASSOCIATED WITH HYPOGLYCEMIA-RELATED HOSPITALIZATION AMONG ELDERLY PATIENTS WITH T2DM IN THE UNITED STATES: A NOVEL APPROACH USING INFLUENTIAL VARIABLE ANALYSIS
Curtis BH1, Schuster DP2, Xie W3, Fu H3
1Eli Lilly and Company, Carmel, IN, USA, 2Eli Lilly & Co., Indianapolis, IN, USA, 3Eli Lilly and Company, Indianapolis, IN, USA

PDB3
A3
WITHDRAWN

PDB4
A4
CLINICAL EFFICACY AND SAFETY OF INSULIN ASPART COMPARED WITH REGULAR HUMAN INSULIN IN PATIENTS WITH TYPE 1 AND TYPE 2 DIABETES MELLITUS RECEIVING PRANDIAL INSULIN REGIMEN - A SYSTEMATIC REVIEW AND META-ANALYSIS
Wojciechowski P1, Niemczyk-Szechowska P1, Olewinska E1, Jaros P1, Jurkiewicz B2, Skarzynska-Duk J2, Mlalecki MT3, Rys P1
1HTA Consulting, Krakow, Poland, 2Novo Nordisk Pharma, Warszawa, Poland, 3Jagiellonian University Medical College, Krakow, Poland

PDB5
A5
A SYSTEMATIC LITERATURE REVIEW AND EVIDENCE SYNTHESIS OF ANTI-DIABETES TREATMENTS IN TYPE 2 DIABETES MELLITUS PATIENTS: INDIRECT COMPARISON OF EXENATIDE WITH METFORMIN + SULPHONYLUREA
King DT1, Trautmann M2, Sabater J3, Pahor A4, Shaw JW2, Grandy S5, Budd D3, Batson S1
1Abacus International, Bicester, UK, 2Diabetes Research, Hamburg, Germany, 3Bristol-Myers Squibb EMEA SARL, Paris, France, 4Astra Zeneca GmbH, Wedel, Germany, 5AstraZeneca LP, Wilmington, DE, USA

PDB6
A6
THE POTENTIAL CARDIOVASCULAR RISK OF ROSIGLITAZONE COMPARING TO OTHER ANTI-DIABETES AGENTS: A RETROSPECTIVE DESCRIPTIVE STUDY
Deng Y, Guo JJ, Lin AC
University of Cincinnati College of Pharmacy, Cincinnati, OH, USA

PDB7
A7
RATE OF ANAPHYLAXIS ASSOCIATED WITH INTRAMUSCULAR TESTOSTERONE INJECTIONS
Ma L1, Summers KH2, Camper SB1, Shusterman NH1
1Endo Pharmaceuticals Inc., Malvern, PA, USA, 2, West Chester, PA, USA

PDB8
A8
CLINICAL OUTCOMES AMONG ELDERLY MEDICARE BENEFICIARIES HAVING CHRONIC ILLNESS WITH COMPLEXITY: A MEDICARE ADVANTAGE POPULATION STUDY
Bhattacharjee S1, Pan X2, Sambamoorthi U1
1West Virginia University, Morgantown, WV, USA, 2West Virginia University School of Pharmacy, Morgantown, WV, USA

PDB9
A9
EFFECT OF THYROID HORMONE LEVELS ON ALPHA HUMAN HERPES VIRUSES LATENCY AND REACTIVATION
Parmar JR, Ajavon A, Balish M, Hsia V, Freeman R
University of Maryland Eastern Shore, Princess Anne, MD, USA

PDB10
WITHDRAWN

PDB11
A10
COMPOSITE QUALITY MEASURE (CQM) ATTAINMENT IN OVERWEIGHT/OBESE PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH CANAGLIFLOZIN 300 MG (CANA) OR SITAGLIPTIN 100 MG (SITA)
Bailey RA1, Vijapurkar U2, Martin S1, Meininger G2, Rupnow MF1
1Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Janssen Research and Development, Raritan, NJ, USA

PDB12
A11
CLINICAL EFFECTIVENESS OF SURGICAL THERAPIES, RADIOTHERAPY AND MEDICAL INTERVENTIONS IN CUSHING 'S DISEASE; A SYSTEMATIC LITERATURE REVIEW
Shahmoon V1, Rousseau G1, Koch C2, Hurry M3
1University of Montreal, Montréal, QC, Canada, 2Novartis Pharmaceuticals Canada, Dorval, QC, Canada, 3Novartis Pharmaceuticals Canada Inc., Dorval, QC, Canada

PDB13
A12
META-ANALYSIS OF BARIATRIC SURGERY IN PATIENTS WITH TYPE 2 DIABETES IN CHINA
Yu J1, Li Y1, Zhou X1, Liu G1, Sun X1, Yue N2
1West China Hospital, Sichuan University, Chengdu, China, 2Johnson & Johnson Medical China, Beijing, China

PDB14
A13
ASSESSMENT OF EVIDENCE ON THE EFFECTIVENESS OF SELF-MONITORING BLOOD GLUCOSE (SMBG) IN DIABETES PATIENTS TREATED WITH INSULIN IN LATIN AMERICA
Junqueira SM1, Andrade PC1, Cachoeira CV1, Repsold DM1, Sadik K2
1Johnson & Johnson Medical, São Paulo, Brazil, 2Johnson & Johnson Medical, Raynham, MA, USA

PDB15
A14
CLINICAL OUTCOMES OF DAPAGLIFLOZIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS: A META-ANALYSIS OF RANDOMISED CONTROLLED CLINICAL TRIALS
Raval A1, Thakker D2, Undela K3, Vyas A1, Kachhadiya R4, Ubhadiya B5
1West Virginia University, Morgantown, WV, USA, 2Capita India Pvt. Ltd., Mumbai, Maharastra, India, 3JSS College of Pharmacy, Mysore, Karnataka, India, 4Cadila Healthcare Ltd., Ahmedabad, Gujarat, India, 5Shrimati Kaumudiniben Health Outcomes Research Group, Dhrangadhra, India

PDB16
A15
THE RISK OF DEVELOPING TYPE II DIABETES IN CHILDREN AND ADOLESCENTS USING ATYPICAL ANTIPSYCHOTICS
Sohn M, Talbert J, Blumenschein K, Moga DC
University of Kentucky, Lexington, KY, USA

PDB17
A16
GLUCOSE-LOWERING WITH EXOGENOUS INSULIN MONOTHERAPY IN TYPE 2 DIABETES: DOSE-RESPONSE ASSOCIATION WITH ALL-CAUSE MORTALITY, CARDIOVASCULAR EVENTS, AND INCIDENT CANCER
Holden SE1, Jenkins-Jones S2, Morgan CL2, Schernthaner G3, Currie CJ1
1Cardiff University, Cardiff, UK, 2Pharmatelligence, Cardiff, UK, 3Rudolfstiftung Hospital Vienna, A - 1030 Vienna, Austria

PDB18
B1
PROPORTION OF PATIENTS WITH UNCONTROLLED TYPE 2 DIABETES RECEIVING RECOMMENDED DIABETES TREATMENT AMONG WHITES AND MEXICAN AMERICANS: NHANES 2003-2010
Perez A1, Elrod S2, Sanchez J1
1Nova Southeastern University College of Pharmacy, Fort Lauderdale, FL, USA, 2UNT System College of Pharmacy, Fort Worth, FL, USA

PDB19
B2
FRAMINGHAM RISK SCORE ESTIMATES HIGHER CVD RISK THAN UKPDS RISK ENGINE IN NEWLY DIAGNOSED TYPE 2 DIABETES MELLITUS PATIENTS IN NORTH INDIA
Smruthi Raj N R1, Bansal D2, Bhansali A3
1National Institute of Pharmaceutical Research and Education, Mohali, Punjab,, India, 2National Institute of Pharmaceutical Research and Education, Mohali, Punjab, India, 3Post Graduate Institute of Medical Education and Research

PDB20
B3
THE IMPACT OF CONCOMITANT METFORMIN ON MORTALITY AND OTHER SERIOUS OUTCOMES IN PEOPLE WITH TYPE 2 DIABETES TREATED WITH INSULIN
Holden SE, Currie CJ
Cardiff University, Cardiff, UK

PDB21
B4
STATUS OF RETINOPATHY IN TYPE 2 DIABETES MELLITUS PATIENTS OF NORTH INDIAN POPULATION
Esam HP1, Bansal D2, Gudala K1, Bhansali A3
1National Institute of Pharmaceuitical Education and Research, Mohali, India, 2National Institute of Pharmaceutical Research and Education, Mohali, Punjab, India, 3Post Graduate Institute of Medical Education and Research

PDB22
B5
REGIONAL ESTIMATES OF THE PREVALENCE OF DIABETES MELLITUS IN GERMANY FOR 2011 AND 2022 BASED ON PRESCRIPTION DATA
Willert T1, Walker J2, Frenzel A2, Schramm W1
1Heilbronn University, Heilbronn, Germany, 2IMS HEALTH, Frankfurt/Main, Germany

PDB23
B6
CHANGES IN PATIENT CHARACTERISTICS AND TREATMENT PATTERNS AMONG PATIENTS WITH TYPE 2 DIABETES IN THE US FROM 2006-2013
Annunziata K1, Sternbach N2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA

PDB24
B7
PREVALENCE AND ECONOMIC BURDEN OF DIABETES IN AFRICA
Ondere L, Garfield S, Hertz D
GfK Market Access, Wayland, MA, USA

PDB25
B8
EXAMINING DIABETES PREVALENCE IN THE UNITED STATES USING A 2008-2009 MEDICAID POPULATION
Wang L1, Xie L2, Zhang J3, Shrestha S1, Wang Y2, Baser O4
1STATinMED Research, Plano, TX, USA, 2STATinMED Research, Ann Arbor, MI, USA, 3STATinMED Research, Dallas, TX, USA, 4STATinMED Research and The University of Michigan, Ann Arbor, MI, USA

PDB26
B9
THE OPTIMAL INTERVAL OF DIABETES MELLITUS SCREENING IN HEALTHY ADULTS: A RANDOM EFFECTS MODEL
Takahashi O, Ohde S
St.Luke's Life Science Institute, Tokyo, Japan

PDB27
B10
IDENTIFICATION OF DETERMINANTS OF PROGRESSION TO TYPE 2 DIABETES USING ELECTRONIC HEALTH RECORDS AND 'BIG DATA' ANALYTICS
Anderson JP1, Parikh JR1, Shenfeld DK1, Church BW1, Laramie JM1, Piper BA2, Willke RJ2, Mardekian J2, Rublee DA2
1GNS Healthcare, Cambridge, MA, USA, 2Pfizer, Inc., New York, NY, USA

DIABETES/ENDOCRINE DISORDERS - Cost Studies
PDB28
B11
BUDGET IMPACT ANALYSIS OF VILDAGLIPTIN AS ADDITION TO ANALOGUE INSULINS IN TYPE 2 DIABETES MELLITUS TREATMENT IN COLOMBIA
Romero M1, Marrugo R1, Acero G1, Karpf Benavides E2
1Fundacion Salutia, Bogota, Colombia, 2Novartis, Bogota, Colombia

PDB29
B12
BUDGET IMPACT OF PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE (PHEN/TPM ER) IN OVERWEIGHT AND OBESE PATIENTS WITH COMORBID PREDIABETES OR TYPE 2 DIABETES MELLITUS (T2DM)
Zagadailov E1, Carlton R1, Bramley T1, Liu W2, Karnawat S2, McDowell J2
1Xcenda, Palm Harbor, FL, USA, 2VIVUS, Inc., Mountain View, CA, USA

PDB30
B13
SAXAGLIPTIN/METFORMIN EXTENDED-RELEASE (XR) FOR THE TYPE 2 DIABETES (T2DM) TREATMENT IN VENEZUELA: A BUDGET IMPACT ANALYSIS
Elgart JF1, Gonzalez L2, Perez Monteverde A3, Garrido Lecca S4, Aiello E5, Gagliardino JJ2
1CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro Colaborador OPS/OMS), La Plata, Buenos Aires, Argentina, 2CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro Colaborador OPS/OMS), Buenos Aires, Argentina, 3Centro Médico Docente la Trinidad, Caracas, Venezuela, 4Bristol-Myers Squibb Company, Lima, Peru, 5Bristol-Myers Squibb Company, Buenos Aires, Argentina

PDB31
B14
BUDGET IMPACT ANALYSIS OF UTILIZING CANAGLIFLOZIN (CANA) FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN A US HEALTH PLAN
Vo L, Martin S
Janssen Scientific Affairs, LLC, Raritan, NJ, USA

PDB32
B15
BUDGET IMPACT ANALYSIS OF INSULIN ANALOGUES FOR TYPE 1 DIABETES: THE CASE OF THE BRAZILIAN PUBLIC HEALTH SYSTEM (SUS)
Laranjeira F, Mega TP, Lima LP, Salomon FC, Petramale C
Brazilian Ministry of Health, Brasília-DF, Brazil

PDB33
B16
WITHDRAWN

PDB34
C1
SOMATROPIN DOSE ANALYSIS FOR TREATMENT OF HYPOPITUITARISM IN PUBLIC BRAZILIAN HEALTH SYSTEM (SUS)
Ferreira CN, Rufino CS, Manfrin DF
Pfizer, Inc., São Paulo, Brazil

PDB35
C2
IMPACT OF DIABETES IN FAMILY HEALTH SPENDING IN BRAZILIAN POPULATION
Zaccolo A1, Carraro WH1, Rosa Rd1, Duncan BB1, Prince D2
1Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, 2University of Washington, Seattle, WA, USA

PDB36
C3
DIET MODIFICATION IN PATIENTS WITH DIABETES AND ITS ASSOCIATION WITH HEATH CARE UTILIZATION AND EXPENDITURE
Alfaifi A1, Althemery AU1, Lai L2
1Nova Southeastern University, Plantation, FL, USA, 2Nova Southeastern University, Ft. Lauderdale, FL, USA

PDB37
C4
TREATMENT OF BRAZILIAN CHILDREN WITH GROWTH HORMONE DEFICIENCY AND TURNER SYNDROME: IMPLICATIONS OF A DATA-DRIVEN APPROACH TO GUIDE DECISIONS
Silva MA1, Mello IM1, Fernandes RA1, Almeida BG1, Ferreira CN2, Loftus J3
1ANOVA, Rio de Janeiro, Brazil, 2Pfizer, Inc., São Paulo, Brazil, 3Pfizer Ltd, Tadworth, UK

PDB38
C5
COMPARISON OF THE DOUBLY ROBUST ESTIMATION METHOD TO THE PROPENSITY SCORE METHOD IN A DIABETES-RELATED COMPARATIVE HEALTH ECONOMICS STUDY
Sun P1, Lian J2
1Kailo Research Group, Indianapolis, IN, USA, 2Novo Nordisk Inc., Princeton, NJ, USA

PDB39
C6
HEALTHCARE COSTS AMONG TYPE 2 DIABETES MELLITUS PATIENTS INITIATING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA) THERAPY
Johnston SS1, Nguyen H2, Felber E2, Cappell K1, Nelson J1, Chu B3, Kalsekar I2
1Truven Health Analytics, Bethesda, MD, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Truven Health Analytics, Santa Barbara, CA, USA

PDB40
C7
COMPARATIVE COST ANALYSIS FOR TREATING GROWTH HORMONE DEFICIENCE IN BRAZIL: PEN VERSUS SYRINGES
Silva MA1, Mello IM1, Fernandes RA1, Almeida BG1, Manfrin DF2, Ferreira CN2
1ANOVA, Rio de Janeiro, Brazil, 2Pfizer, Inc., São Paulo, Brazil

PDB41
C8
HEALTHCARE RESOURCE UTILIZATION AND COSTS ASSOCIATED WITH VARIOUS STAGES OF CHRONIC KIDNEY DISEASE AMONG TYPE 2 DIABETES MELLITUS PATIENTS
Chuang C1, Lee E2, Yang E1, Tawah A1, Ghosh S2, Chen S1
1Evidera, Lexington, MA, USA, 2Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, USA

PDB42
C9
IMPACT OF DIABETES ON EXPENDITURES ASSOCIATED WITH SOFT SKIN AND TISSUE INFECTIONS
Ye Y, McConeghy R, Pawar AM, Caffrey A
University of Rhode Island, Kingston, RI, USA

PDB43
WITHDRAWN

PDB44
C10
CHARGES AND HEALTHCARE RESOURCE USE IN PATIENTS WITH TYPE 2 DIABETES MELITUS AFTER TREATMENT INITIATION WITH SAXAGLIPTIN OR SITAGLIPTIN
Sheehan J1, Moorthy V2, Colilla S3, Kalsekar I1
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Mu Sigma Inc., Hopewell, NJ, USA, 3Bristol-Myers Squibb, Hopewell, NJ, USA

PDB45
C11
CONTINUOUS GLUCOSE MONITORING SYSTEMS: TRENDS IN UPTAKE, PATIENT COSTS, AND RESOURCE UTILIZATION
Gatwood J1, Johnson BH2
1University of Michigan, Ann Arbor, MI, USA, 2Truven Health Analytics, Bethesda, MD, USA

PDB46
C12
LIRAGLUTIDE: A PHARMACOECONOMIC REVIEW OF ITS USE IN TYPE II DIABETES
Schultz NM1, Zueger PM2
1University of Arizona, Tucson, AZ, USA, 2University of Illinois at Chicago, Chicago, IL, USA

PDB47
C13
LIFE YEARS LOST AND LIFETIME HEALTHCARE EXPENDITURES ASSOCIATED WITH DIABETES IN THE UNITED STATES
Leung MY, Chang S, Pollack L, Colditz GA
Washington University, St. Louis, MO, USA

PDB48
C14
HETEROGENEITY OF HEALTHCARE COSTS AMONG MEDICARE ADVANTAGE PATIENTS WITH TYPE 1 DIABETES
Clore GS1, Slabaugh SL1, Curtis BH2, Fu H2, Schuster DP2
1Comprehensive Health Insights, Inc., Louisville, KY, USA, 2Eli Lilly & Co., Indianapolis, IN, USA

PDB49
C15
BURDEN OF ILLNESS OF DIABETIC FOOT ULCERS IN CANADA
Hopkins RB, Burke N, Harlock J, Jegathisawaran J, Goeree R
McMaster University, Hamilton, ON, Canada

PDB50
C16
ECONOMIC BURDEN OF DIABETIC PATIENTS IN PRIVATE AND PUBLIC HOSPITALS
Lohani SP
Center for Health Research and International Relations, Nobel College, Pokhara University, Kathmandu, Nepal

PDB51
D1
DIRECT AND INDIRECT COST OF DIABETES IN ITALY: A PREVALENCE PROBABILISTIC APPROACH
Viti R1, Marcellusi A2, Mennini FS1
1University of Rome “Tor Vergata”, Italy, Rome, Italy, 2University of Rome “Tor Vergata”, Rome, Italy

PDB52
D2
ESTIMATING THE BURDEN OF ILLNESS OF PAINFUL DIABETIC PERIPHERAL NEUROPATHY IN CHINA
Wang B1, Xie XP2, Furnback W1, Ney JP3, Chen C2
1Alliance Life Sciences, Somerset, NJ, USA, 2Pfizer Inc., Beijing, China, 3University of Washington, Seattle, WA, USA

PDB53
D3
COSTS OF SELF-MONITORING OF BLOOD GLUCOSE AND SELF-INJECTION OF INSULIN FOR PATIENTS WITH TYPE 2 DIABETES IN BEIJING AND TIANJIN: ESTIMATING COSTS OF SELF-USED DEVICES AND SUPPLIES
Dong CH1, Zhong J2
1Ministry of Human Resources and Social Security, China, Beijing, China, 2Peking University, Beijing, China

PDB54
D4
FREQUENCY, COST, AND INFLUENCE FACTORS OF INSULIN PEN NEEDLES REUSE FOR PATIENTS WITH DIABETES IN CHINA
Li H1, Ruan Z2, Guan X1, Guo Z3, Sun F2, Shi L1
1International Research Center of Medicinal Administration, Peking University, Beijing, China, 2Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China, 3School of Pharmaceutical Sciences, Peking University, Beijing, China

PDB55
D5
PREVALENCE, FREQUENCY AND COST OF SELF-MONITORING OF BLOOD GLUCOSE AND ITS INFLUENCING FACTORS FOR INSULIN-TREATED DIABETES PATIENTS IN CHINA
Li H1, Ruan Z2, Guan X1, Guo Z3, Sun F2, Shi L1
1International Research Center of Medicinal Administration, Peking University, Beijing, China, 2Novo Nordisk (China) Pharmaceuticals Co., Ltd., Beijing, China, 3School of Pharmaceutical Sciences, Peking University, Beijing, China

PDB56
D6
DAPAGLIFLOZIN VERSUS SULFONYLUREA AS AN ADD-ON THERAPY TO METFORMIN: A COST-EFFECTIVENESS ANALYSIS IN COLOMBIA
Elgart JF1, Prestes M2, Gonzalez L3, Aschner P4, Garrido Lecca S5, Aiello E6, Jimenez C7, Gagliardino JJ3
1CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro Colaborador OPS/OMS), La Plata, Buenos Aires, Argentina, 2CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), La Plata, Argentina, Buenos Aires, Argentina, 3CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro Colaborador OPS/OMS), Buenos Aires, Argentina, 4Pontificia Universidad Javeriana, Bogota, Colombia, 5Bristol-Myers Squibb Company, Lima, Peru, 6Bristol-Myers Squibb Company, Buenos Aires, Argentina, 7Bristol-Myers Squibb Company, Bogota, Colombia

PDB57
D7
COST-EFFECTIVENESS ANALYSIS OF BIPHASIC INSULIN ASPART VERSUS INSULIN GLARGINE IN PEOPLE WITH TYPE 2 DIABETES IN CHINA
Xu Z1, Han P2, Wei Y3, Zhang Y4, Wu J5
1The 306th Hospital of PLA, Beijing, China, 2Shengjing Hospital of China Medical University, Shenyang, China, 3City East Hospital, Shanghai, China, 4Novonordisk(China) Pharmaceuticals Co., Ltd., Beijing, China, 5Tianjin University, Tianjin, China

PDB58
D8
MODELING THE LONG-TERM COSTS AND OUTCOMES OF ANTIDIABETICS IN PATIENTS WITH TYPE 2 DIABETES AT HIGH RISK OF CARDIOVASCULAR EVENTS
Zheng Y1, Sorensen S1, Palencia R2, Ruffolo A3, Hass B3, Kansal A1
1Evidera, Bethesda, MD, USA, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany, 3Boehringer Ingelheim GmbH, Ingelheim, Germany

PDB59
D9
COST-EFFECTIVENESS OF CLOSTRIDIAL COLLAGENASE OINTMENT ON WOUND CLOSURE IN PATIENTS WITH DIABETIC FOOT ULCER
Gilligan AM1, Lange DL1, Motley TA2, Waycaster C1, Dickerson JE1
1Smith & Nephew Biotherapeutics, Fort Worth, TX, USA, 2University of North Texas Health Sciences Center, Fort Worth, TX, USA

PDB60
D10
HEALTH ECONOMIC EVALUATION OF CANAGLIFLOZIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN BELGIUM
Lamotte M1, Wyffels V2, Knudsen MS3, Troelsgaard A4, Hemels M4
1IMS Health HEOR, Vilvoorde, Belgium, 2Janssen-Cilag, Beerse, Belgium, 3IMS Health, London, UK, 4Janssen A/S, Birkerød, Denmark

PDB61
D11
TREATMENT OF TYPE 2 DIABETES IN COLOMBIA: ECONOMIC EVALUATION OF SAXAGLIPTIN/METFORMIN EXTENDED-RELEASE (XR) FIXED-DOSE COMBINATION (FDC)
Elgart JF1, Prestes M2, Gonzalez L3, Garrido Lecca S4, Aiello E5, Jimenez C6, Gagliardino JJ3
1CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro Colaborador OPS/OMS), La Plata, Buenos Aires, Argentina, 2CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), La Plata, Argentina, Buenos Aires, Argentina, 3CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro Colaborador OPS/OMS), Buenos Aires, Argentina, 4Bristol-Myers Squibb Company, Lima, Peru, 5Bristol-Myers Squibb Company, Buenos Aires, Argentina, 6Bristol-Myers Squibb Company, Bogota, Colombia

PDB62
D12
COST-EFFECTIVENESS ANALYSIS OF CANAGLIFLOZIN (CANA) VERSUS DAPAGLIFLOZIN (DAPA) AS AN ADD-ON TO METFORMIN (MET) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) IN THE UNITED STATES
Neslusan C1, Teschemaker A1, Martin S2, Willis M3, Johansen P4
1Janssen Global Services, LLC, Raritan, NJ, USA, 2Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 3The Swedish Institute for Health Economics, Lund, Sweden, 4The Swedish Institute for Health Economics (IHE), Lund, Sweden

PDB63
D13
DAPAGLIFLOZIN: COST-EFFECTIVENESS AS AN ADD-ON THERAPY TO METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES (T2DM) IN ARGENTINA AND CHILE
Elgart JF1, Prestes M2, Gonzalez L3, Asteazaran S2, Aiello E4, Garrido Lecca S5, Alvarez A4, Roberts M4, Cortes Cuadra P6, Gagliardino JJ3
1CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro Colaborador OPS/OMS), La Plata, Buenos Aires, Argentina, 2CENEXA. Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata), La Plata, Argentina, Buenos Aires, Argentina, 3CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro Colaborador OPS/OMS), Buenos Aires, Argentina, 4Bristol-Myers Squibb Company, Buenos Aires, Argentina, 5Bristol-Myers Squibb Company, Lima, Peru, 6Bristol-Myers Squibb Company, Santiago, Chile

PDB64
D14
COMPARATIVE COST-EFFECTIVENESS OF BECAPLERMIN GEL ON WOUND HEALING AND AMPUTATION IN PATIENTS WITH DIABETIC FOOT ULCER
Gilligan AM, Waycaster C
Smith & Nephew Biotherapeutics, Fort Worth, TX, USA

PDB65
D15
COST-EFFECTIVENESS OF SMALL INTESTINAL SUBMUCOSA EXTRACELLULAR MATRIX ON WOUND CLOSURE IN PATIENTS WITH DIABETIC FOOT ULCER
Gilligan AM, Waycaster C
Smith & Nephew Biotherapeutics, Fort Worth, TX, USA

PDB66
D16
ADDING VILDAGLIPTIN TO STANDARD CARE IN PATIENTS WITH TYPE 2 DIABETES IN COLOMBIA- A COST-EFFECTIVENESS ANALYSIS
Vecino AI1, Diaz-Sotelo OD2, Karpf Benavides E3, Quijano M4, Parra C5, Alfonso-Cristancho R6
1RANDOM Foundation, Bogota, Colombia, 2RANDOM Foundation, Bogota, DC, Colombia, 3Novartis, Bogota, Colombia, 4Novartis Pharma AG, Basel, Switzerland, 5Clinicos IPS, 6University of Washington, Seattle, WA, USA

PDB67
E1
COMPARATIVE COST-EFFECTIVENESS OF BECAPLERMIN GEL ON WOUND HEALING IN PATIENTS WITH DIABETIC FOOT ULCER: CHANGES IN WOUND SURFACE AREA
Waycaster C, Gilligan AM
Smith & Nephew Biotherapeutics, Fort Worth, TX, USA

PDB68
E2
COMPARATIVE COST EFFECTIVENESS OF METFORMIN-BASED ORAL HYPOGLYCEMIC THERAPY IN POPULATION-BASED DATABASE
Ou H, Chen M, Chen Y
National Cheng Kung University, Tainan, Taiwan

PDB69
E3
COST-EFFECTIVENESS OF LIRAGLUTIDE FOR SUBJECTS WITH TYPE 2 DIABETES IN SPAIN
Ramírez de Arellano A1, Hunt B2, Mezquita Raya P3, Briones T1, Pérez A4, Valentine WJ2
1Novo Nordisk Pharma SA, Madrid, Spain, 2Ossian Health Economics and Communications, Basel, Switzerland, 3Hospital Torrecardenas, Clinica San Pedro, Almería, Spain, 4Hospital de la Santa Creu I Sant Pau, Barcelona, Spain

PDB70
E4
COMPARING THE PROJECTED COST PER HBA1C REDUCTION OF EXENATIDE QW VERSUS LIRAGLUTIDE 1.8 MG FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS USING ALTERNATE DATA SOURCES
Wang B1, Nguyen H2, Felber E2, Furnback W1, Roth J3, Garrison L4
1Alliance Life Sciences, Somerset, NJ, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Group Health Cooperative, Seattle, WA, USA, 4School of Pharmacy, University of Washington, Seattle, WA, USA

PDB71
E5
COST-EFFECTIVENESS ANALYSIS OF HCG AND HUMAN GONADOTROPINS IN MEN WITH HYPOGONADOTROPIC HYPOGONADISM IN THE CONTEXT OF AN ASSISTED REPRODUCTION PROGRAM
Chamberland C
Institut national d'excellence en santé et en services sociaux, Québec, QC, Canada

PDB72
E6
HEALTH ECONOMIC EVALUATION OF CANAGLIFLOZIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SWEDEN
Troelsgaard A1, Knudsen MS2, Kjellberg J3, Schmidt A4, Hemels M1
1Janssen A/S, Birkerød, Denmark, 2IMS Health, London, UK, 3Zefferin Farma AB, Stockholm, Sweden, 4Janssen A/S

PDB73
E7
ECONOMIC EVALUATION OF BLOOD GLUCOSE POINT–OF–CARE TESTING IN THE INTENSIVE CARE UNIT
Steuten LM1, Kip M2, Hooijdonk R3, Monteban H4, Spronk P5, Schultz M3
1University of Twente, Enschede, The Netherlands, 2PANAXEA bv, Enschede, The Netherlands, 3Amsterdam Medical Center/University of Amsterdam, Amsterdam, The Netherlands, 4Monteban Value Services, Amerongen, The Netherlands, 5Gelre Hospitals, Apeldoorn, Gelderland, The Netherlands

PDB74
E8
COST-EFFECTIVENESS OF SWITCHING TO BIPHASIC INSULIN ASPART FROM HUMAN PREMIX INSULIN IN PEOPLE WITH TYPE 2 DIABETES IN CHINA
Xiao J1, Bian X2, Zhang Y3, Yang L4
1China-Japan Friendship Hospital, Beijing, China, 2Ruijin Hospital (Luwan), Shanghai, China, 3Novonordisk(China) Pharmaceuticals Co., Ltd., Beijing, China, 4Peking University, Beijing, China

PDB75
E9
COST-EFFECTIVENESS OF SAXAGLIPTIN AND LINAGLIPTIN IN COMBINATION WITH METFORMIN FOR TYPE II DIABETES: A DECISION-TREE ANALYSIS MODEL
Sawant RV1, Sansgiry SS2
1University Of Houston, Houston, TX, USA, 2University of Houston, Houston, TX, USA

PDB76
E10
WEIGHT GAIN, HYPOGLYCAEMIA AND COST-EFFECTIVENESS: WHAT DRIVES VALUE AMONG TYPE 2 DIABETES TREATMENTS IN THE SHORT TERM
Gordon J1, Bell K2, Shah M2, Ward T3, McEwan P4
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2Bristol-Myers Squibb, New York, NY, USA, 3Health Economics and Outcomes Research Ltd, Monmouth, UK, 4Health Economics and Outcomes Research Ltd., Cardiff, UK

PDB77
E11
SHORT-TERM ECONOMIC AND CLINICAL OUTCOMES OF CANAGLIFLOZIN COMPARED TO SITAGLIPTIN IN THE MANAGEMENT OF TYPE 2 DIABETES MELLITUS (T2DM)
Lopez JM1, Martin S1, Ektare V2, Patel D3, Rupnow MF1, Botteman MF2
1Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2Pharmerit International, Bethesda, MD, USA, 3Pharmerit North America LLC, Bethesda, MD, USA

PDB78
E12
THE COST-EFFECTVENESE OF LIRAGLUTIDE VS EXENATIDE FOR THE TREATMENT OF TYPE 2 DIABETES IN THE UNITED STATES
Ning N, Hay JW
Schaeffer Center for Health Policy & Economic, Los Angeles, CA, USA

PDB79
E13
CONTRASTING COST EFFECTIVENESS RESULTS DERIVED FROM THE UKPDS 68 AND 82 RISK EQUATIONS IN TYPE 2 DIABETES
McEwan P1, Foos V2, Grant D3
1Health Economics and Outcomes Research Ltd., Cardiff, UK, 2IMS Health, Basel, Switzerland, 3IMS Health, London, UK

PDB80
E14
ILLUSTRATING THE RELATIONSHIP BETWEEN THE NUMBER OF HYPOGLYCAEMIA EVENTS, EVENT RATE REDUCTION AND THE IMPACT ON ESTIMATES OF QUALITY OF LIFE IMPROVEMENT IN HEALTH ECONOMIC STUDIES
Foos V1, McEwan P2, Grant D3
1IMS Health, Basel, Switzerland, 2Health Economics and Outcomes Research Ltd., Cardiff, UK, 3IMS Health, London, UK

PDB81
E15
VALIDATING THE UKPDS 82 RISK EQUATIONS TO CONTEMPORARY OUTCOMES STUDIES IN TYPE 2 DIABETES
Grant D1, Foos V2, McEwan P3
1IMS Health, London, UK, 2IMS Health, Basel, Switzerland, 3Health Economics and Outcomes Research Ltd., Cardiff, UK

PDB82
E16
ASSESSING SIMULATION RUN TIME REQUIREMENTS TO ACHIEVE STABILIZED ABSOLUTE AND INCREMENTAL COST EFFECTIVENESS RESULTS IN TYPE 2 DIABETES: A STUDY USING THE IMS CORE DIABETES MODEL
Foos V1, Grant D2, McEwan P3
1IMS Health, Basel, Switzerland, 2IMS Health, London, UK, 3Health Economics and Outcomes Research Ltd., Cardiff, UK

PDB83
F1
COST-UTILITY ANALYSES IN DIABETES: A SYSTEMATIC REVIEW AND POTENTIAL GAINS FROM USING ECONOMIC EVIDENCE
Zhong Y1, Lin P1, Cohen JT2, Winn A3, Neumann PJ1
1Tufts Medical Center, Boston, MA, USA, 2Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA, 3University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

PDB84
F2
WEIGHT CHANGE AND HEALTH CARE RESOURCE USE (HCRU) IN ENGLISH PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING A NEW ANTIDIABETIC DRUG CLASS
Rigney U1, Blak BT1, Sternhufvud C2, Ycas J3, Racketa J3, Hammar N2
1AstraZeneca UK Ltd, Luton, UK, 2AstraZeneca, Mölndal, Sweden, 3AstraZeneca Pharmaceuticals US, Wilmington, DE, USA

PDB85
F3
IMPACT OF HEALTH INSURANCE STATUS ON HEALTHCARE RESOURCE UTILIZATION AMONG DIABETIC PATIENTS IN THE USA
Dabbous FM1, Dorey J2, Thokagevistk K3, Toumi M4
1University of Illinois at Chicago, Chicago, IL, USA, 2Creativ-Ceutical USA, Chicago, IL, USA, 3Creativ-Ceutical, Chicago, IL, USA, 4University Claude Bernard Lyon 1, Lyon, France

PDB86
F4
METHODOLOGICAL CHALLENGES IN CALCULATION OF DAILY AVERAGE CONSUMPTION (DACON) FOR GLP-1 RECEPTOR AGONIST INJECTABLES FROM CLAIMS DATA
Swindle R1, Yu M2, Xie J2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Eli Lilly and Company, Toronto, ON, Canada

PDB87
F5
HEALTH CARE UTILIZATION AND DIRECT ECONOMIC BURDEN OF DIABETES PATIENTS UNDER ONE URBAN HEALTH INSURANCE SCHEME OF CHINA
Chen W1, Lou J2, Zhu J2
1Center for Pharmacoeconomic Research and Evaluation, School of Public Health, Fudan University, Shanghai, China, 2Fudan University, Shanghai, China

DIABETES/ENDOCRINE DISORDERS - Patient-Reported Outcomes & Patient Preference Studies
PDB88
F6
EXAMINING A THRESHOLD OF ADHERENCE TO ORAL HYPOGLYCEMIC AGENTS RELEVANT TO CLINICAL OUTCOMES IN DIABETES: A TREE-STRUCTURED SURVIVAL MODEL
Lo-Ciganic W1, Donohue JM1, Thorpe CT2, Thorpe JM2, Perera S1, Marcum ZA1, Gellad WF3
1University of Pittsburgh, Pittsburgh, PA, USA, 2University of Pittsburgh, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, 3VA Pittsburgh Health Care System, RAND, and University of Pittsburgh, pittsburgh, PA, USA

PDB89
F7
ACUTE-PHASE PERSISTENCE WITH ANTIDEPRESSANT THERAPY AND ASSOCIATED MEDICATION COST AMONG PATIENTS WITH DIABETES: AN ANALYSIS OF COMMERCIALLY INSURED PATIENTS IN RHODE ISLAND
Chinthapatla H1, Kogut S2, Paine D3
1University of Rhode Island, Kingston, RI, USA, 2University of RI, Kingston, RI, USA, 3Blue Cross Blue Shield, Providence, RI, USA

PDB90
F8
DIABETES PATIENTS ARE MORE ADHERENT THAN PLANS REALIZE
Wilson PR, Morini L, Henderson S, Dockery JD
Adheris, Blue Bell, PA, USA

PDB91
F9
LONG-TERM ADHERENCE AND PERSISTENCE WITH DPP-4I ENZYME INHIBITORS IN ADULTS WITH TYPE 2 DIABETES
Farr AM1, Sheehan J2, Curkendall SM3, Smith DM4, Johnston SS4, Kalsekar I2
1Truven Health Analytics Inc, Cambridge, MA, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Truven Health Analytics, Bend, OR, USA, 4Truven Health Analytics, Bethesda, MD, USA

PDB92
F10
PERSISTENCE OF TESTOSTERONE REPLACEMENT THERAPY (TRT) IN THE US
Puenpatom RA, Camper SB, Ma L
Endo Pharmaceuticals Inc., Malvern, PA, USA

PDB93
F11
PERFORMANCE OF THE NATIONAL QUALITY FORUM DIABETES ADHERENCE MEASURE IN THE MISSISSIPPI MEDICAID POPULATION
Ramachandran S
University of Mississippi, University, MS, USA

PDB94
F12
ADHERENCE BARRIERS TO ACE-IS AND ARBS AMONG NON-ADHERENT HYPERTENSIVE PATIENTS WITH DIABETES ENROLLED IN A MEDICARE ADVANTAGE PLAN
Abughosh S1, Wang X1, Henges C2, Fleming ML1, Serna O2
1University of Houston, Houston, TX, USA, 2Cigna-HealthSpring, houston, TX, USA

PDB95
F13
DEVELOPING A BEHAVIORAL FRAMEWORK FOR COST-RELATED MEDICATION NON-COMPLIANCE AMONG OLDER DIABETES PATIENTS
Zhang J1, Meltzer D2
1The University of Chicago, Chicago, IL, USA, 2University of Chicago, Chicago, IL, USA

PDB96
F14
PERSISTENCE RATE AND ADHERENCE LEVEL TO ORAL ANTIDIABETICS AND THEIR ASSOCIATED DETERMINANTS
Simard P1, Roy L2, Dorais M3, White-Guay B1, Räkel A2, Perreault S1
1Université de Montréal, Montréal, QC, Canada, 2Centre Hospitalier de l'Université de Montréal Hôpital Saint Luc, Montréal, QC, Canada, 3StatSciences Inc., N.-D. de l'Île-Perrot, QC, Canada

PDB97
F15
PEN NEEDLE LENGTH AND PERSISTENCE AMONG INSULIN PEN USERS WITH TYPE 2 DIABETES MELLITUS
Manocchio J1, Chandran A1, Bonafede MM2, Saltiel-Berzin R1, Hirsch LJ1, Lahue BJ3
1BD, Franklin Lakes, NJ, USA, 2Truven Health Analytics, Cambridge, MA, USA, 3Becton Dickinson, Franklin Lakes, NJ, USA

PDB98
WITHDRAWN

PDB99
F16
THE ASSOCIATION OF ADHERENCE AND HEALTH BEHAVIORS WITH HEALTH STATUS AMONG PATIENTS WITH TYPE 2 DIABETES IN JAPAN
DiBonaventura M, Kumar M
Kantar Health, New York, NY, USA

PDB100
G1
WEIGHT SATISFACTION AND AMOUNT OF WEIGHT CHANGE: EVIDENCE FROM A PHASE 3 TRIAL OF CANAGLIFLOZIN (CANA) VS. PLACEBO (PBO)
Traina SB1, Slee A2, Neslusan C1
1Janssen Global Services, LLC, Raritan, NJ, USA, 2Axio, Seattle, WA, USA

PDB101
G2
A DISCRETE CHOICE EXPERIMENT CONDUCTED AMONG PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM THE UNITED STATES
Gelhorn H1, Stringer S2, Lee E3, Palencia R4
1Evidera, Bethesda, MD, USA, 2Evidera, Inc., Bethesda, MD, USA, 3Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USA, 4Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany

PDB102
G3
PATIENT PREFERENCES FOR FREQUENCY OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1RA) INJECTIONS IN THE TREATMENT OF TYPE 2 DIABETES
Hauber AB1, Nguyen H2, Posner J1, Ervin CM1, LaRue S2, Kalsekar I2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA

PDB103
G4
THE IMPACT ON HEALTH RELATED QUALITY OF LIFE OF DIABETES SYMPTOMS AND CONCOMITANT CONDITIONS
Dierick K1, Herterich R2, Pike I3, Dean C3, Mcbride M4, Love T4
1GfK Disease Atlas, Brussels, Belgium, 2GfK, Nürnberg, Germany, 3GfK NOP, London, UK, 4GfK USA, New York, NY, USA

PDB104
G5
SELF-REPORTED MENTAL HEALTH STATUS IN ADULTS WITH DIABETES AND COMORBID DEPRESSION
Bemski J1, Trammel-Fisher D1, McQueen RB2
1Nova Southeastern University, Fort Lauderdale, FL, USA, 2University of Colorado Anschutz Medical Campus, Aurora, CO, USA

PDB105
WITHDRAWN

PDB106
G6
RACIAL DISPARITIES IN TYPE 2 DIABETES MEDICATION ADHERENCE IN MEDICAID ADULTS WITH DEVELOPMENTAL DISABILITIES
Patel I1, Balkrishnan R2, Chang J3, Erickson S1, Bagozzi R1, Caldwell C4, Woolford S4
1The University of Michigan, Ann Arbor, MI, USA, 2University of Michigan, Ann Arbor, MI, USA, 3Samford University, Birmingham, AL, USA, 4University of Michigan, ANN ARBOR, MI, USA

PDB107
G7
RELATIONSHIPS BETWEEN SOCIO-DEMOGRAPHICS AND HEALTH RELATED QUALITY OF LIFE AMONG DIABETES PATIENTS IN THE USA
Dierick K1, Mcbride M2, Love T2, Herterich R3, Pike I4, Dean C4
1GfK Disease Atlas, Brussels, Belgium, 2GfK USA, New York, NY, USA, 3GfK, Nürnberg, Germany, 4GfK NOP, London, UK

PDB108
WITHDRAWN

PDB109
G8
EVALUATING THE RELATIONSHIP BETWEEN BODY MASS INDEX (BMI) AND HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF PATIENTS WITH DIABETES
Adeyemi A1, Rascati KL2, Lawson KA1, Barner JC1, Wilson J1, Novak S1
1The University of Texas at Austin, Austin, TX, USA, 2The University of Texas at Austin, College of Pharmacy, Austin, TX, USA

PDB110
G9
CHANGE IN QUALITY OF LIFE (EQ-5D) AMONG TYPE 2 DIABETES MELLITUS PATIENTS INADEQUATELY CONTROLLED WITH METFORMIN PLUS SULFONYLUREA AND TREATED WITH DAPAGLIFLOZIN AS TRIPLE THERAPY REGIMEN FOR 24 WEEKS
Sternhufvud C1, Rohwedder K2, Sugg J3, Grandy S3
1AstraZeneca, Mölndal, Sweden, 2AstraZeneca R&D, Mölndal, Sweden, 3AstraZeneca LP, Wilmington, DE, USA

PDB111
G10
THE ASSOCIATION OF HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND ACHIEVEMENT OF DISEASE MANAGEMENT GOALS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM)
Traina SB1, Neslusan C1, Slee A2
1Janssen Global Services, LLC, Raritan, NJ, USA, 2Axio, Seattle, WA, USA

PDB112
G11
THE IMPACT OF DAYTIME AND NOCTURNAL NON-SEVERE HYPOGLYCAEMIC EVENTS ON PEOPLE WITH DIABETES IN ALGERIA
Aouiche S1, Guesmi K2, Todorova L3
1Mustapha University Hospital, Algiers, Algeria, 2Novo Nordisk A/S, Algiers, Algeria, 3Novo Nordisk International Operations, Zurich, Switzerland

PDB113
G12
THE IMPACT OF DAYTIME AND NOCTURNAL NON-SEVERE HYPOGLYCAEMIC EVENTS ON PEOPLE WITH DIABETES IN BANGLADESH
Pathan F1, Siddiqui NI2, Sobhan J3, Todorova L4
1BIRDEM, Dhaka, Bangladesh, 2Mymensingh Medical College Hospital, Mymensingh, Bangladesh, 3Novo Nordisk Pharma Limited, Dhaka, Bangladesh, 4Novo Nordisk International Operations, Zurich, Switzerland

PDB114
G13
HEALTH-RELATED QUALITY OF LIFE ANALYSIS FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS TREATED WITH EMPAGLIFLOZIN
Chirila C1, Ziemiecki R1, Davenport E1, Kaschinski D2, Pfarr E2, Palencia R2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany

PDB115
G14
THE IMPACT OF DAYTIME AND NOCTURNAL NON-SEVERE HYPOGLYCAEMIC EVENTS ON PEOPLE WITH DIABETES IN SINGAPORE
Jain A1, Todorova L2
1Novo Nordisk Pharma (Malaysia) Sdn. Bhd., Kuala Lampur, Malaysia, 2Novo Nordisk International Operations, Zurich, Switzerland

PDB116
G15
EFFECT OF NOCTURNAL AND DAYTIME NON-SEVERE HYPOGLYCAEMIC EVENTS ON PEOPLE WITH DIABETES IN MEXICO
Aguilar Garza JL1, Vazquez CE1, Reynoso Mendoza RA2, Guzman Caniupan JA2
1Vitamédica, México D.F., Mexico, 2Novo Nordisk Servicios, México D.F., Mexico

PDB117
G16
UTILISATION OF HEALTHCARE SERVICES AND PATIENT QUALITY OF LIFE FOLLOWING NOCTURNAL AND DAYTIME NON-SEVERE HYPOGLYCAEMIC EVENTS IN PEOPLE WITH DIABETES IN COLOMBIA
Gómez AM1, Cendales Rey JG2, Chaves Cardona R2
1Hospital Universitario de San Ignacio, Universidad Javeriana, Bogotá, Colombia, 2Novo Nordisk Colombia SAS, Bogotá, Colombia

DIABETES/ENDOCRINE DISORDERS - Health Care Use & Policy Studies
PDB118
G17
ROLE OF PATIENTS IN SHARING THE DECISION TO UNDERTAKE BARIATRIC SURGERY FOR TREATMENT OF OBESITY – A GLOBAL MARKET PERSPECTIVE
Chawla AS1, Spinner DS2, Faulkner EC3, Cabra H4, Patkar AD5, Fegelman E6
1Quintiles Consulting, Durham, NC, USA, 2Quintiles, Durham, NC, USA, 3Institute for Pharmacogenomics and Individualized Therapy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA, 4Ethicon Endo-Surgery, Inc, Cincinnat, OH, USA, 5Ethicon, Inc, Somerville, NJ, USA, 6Ethicon, Cincinnati, OH, USA

PDB119
G18
THE IMPACT OF A VALUE-BASED COPAYMENT WAIVER BENEFIT ON MEDICATION USE AND SPENDING BY PATIENT SUBGROUP
Gibson TB1, Maclean R2, Carls G1, Moore BJ1, Ehrlich E1, Baigel C3
1Truven Health Analytics, Ann Arbor, MI, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Bristol-Myers Squibb, New York, NY, USA

PDB120
G19
RETROSPECTIVE COHORT ANALYSIS OF THE PATTERNS AND PREDICTORS OF METFORMIN TREATMENT CHANGE IN A MEDICARE ADVANTAGE PATIENT POPULATION FROM A LARGE NATIONAL HEALTH PLAN
Hazel-Fernandez L1, Xu Y2, Moretz C1, Meah Y3, Baltz J3, Lian J4, Bouchard JR5
1Comprehensive Health Insights, Humana, Miramar, FL, USA, 2Humana, Inc., Louisville, KY, USA, 3Humana Inc., Louisville, KY, USA, 4Novo Nordisk Inc., Princeton, NJ, USA, 5Novo Nordisk Inc., Plainsboro, NJ, USA

PDB121
G20
ASSESSING THE RELATIONSHIP BETWEEN RANDOM GLUCOSE AND ALL-CAUSE MORTALITY
Tang J1, Saith S2, Al Memari Sa2, Aldhaheri A2, Kohut A2
1University of California, San Francisco, CA, USA, 2Harvard University, Boston, MA, USA

PDB122
G21
THE IMPACT OF TREATMENT PATTERNS AND THE RISK OF SEVERE HYPOGLYCAEMIA EVENTS IN TYPE 1&2 DIABETES MELLITUS IN FIVE CENTRAL EUROPEAN COUNTRIES
Jakubczyk M1, Paweska J2, Niewada M3, Rdzanek E2, Dolezal T4, Nagy B5, Saric T6, Czech M7
1Institute of Econometrics, Warsaw School of Economics, Warsaw, Poland, 2HealthQuest spolka z ograniczona odpowiedzialnoscia Sp. K., Warsaw, Poland, 3Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Warsaw, Poland, 4VALUE OUTCOMES, Prague, Czech Republic, 5Healthware Ltd, Budapest, Hungary, 6Promeritus savjetovanje, Zagreb, Croatia, 7Novo Nordisk Pharma Sp z.o.o., Warsaw, Poland

PDB123
H1
COST-EFFECTIVENESS OF THE INTRODUCTION OF A RISK STRATIFIED POPULATION SCREENING FOR TYPE 2 DIABETES IN HUNGARY
Zsólyom A1, Nagy B2, Dessewffy Z3, Steiner T4, Kaló Z2, Vokó Z2
1Syreon Research Institute, Budapest, Hungary, 2Eötvös Loránd University, Budapest, Hungary, 3Novartis Hungary, Budapest, Hungary, 4St. John's Hospital and North-Buda United Institutions, Budapest, Hungary

PDB124
H2
DIRECT COSTS OF DIABETIC SUPPLIES IN THE U.S: AN ANALYSIS USING 2010 MEDICAL EXPENDITURE PANEL SURVEY (MEPS) DATA
Heinrich KH1, Chandran A2
1Columbia University, New York, NY, USA, 2BD, Franklin Lakes, NJ, USA

PDB125
H3
PATIENT EXPERIENCE WITH AND UTILIZATION OF MANUFACTURER-SPONSORED SUPPORT PROGRAMS FOR INJECTABLE DIABETES MEDICATIONS
Spain CV1, Wivel AE2, Wright JJ3, Hahn RM3
1GSK, Philadelphia, PA, USA, 2GSK, King of Prussia, PA, USA, 3Harris Interactive, Rochester, NY, USA

PDB126
H4
REAL LIFE TREATMENT OF DIABETES MELLITUS TYPE 2 PATIENTS: AN ANALYSIS BASED ON A LARGE SAMPLE OF 449,368 GERMAN PATIENTS
Wilke T1, Groth A2, Fuchs A3, Seitz L4, Kienhöfer J4, Lundershausen R5, Maywald U6
1Hochschule Wismar, Wismar, Germany, 2IPAM Wismar, Wismar, Germany, 3AOK Plus, Dresden, Germany, 4Novo Nordisk Pharma GmbH, Mainz, Germany, 5, Erfurt, 6AOK Plus - Die Gesundheitskasse für Sachsen und Thüringen, Dresden, Germany

PDB127
H5
TRENDS OF APPROVAL AND PRICES OF BRAND DIABETES MEDICATIONS
Kwon S1, Seoane-Vazquez E2
1MCPHS University, Boston, MA, USA, 2International Center for Pharmaceutical Economics and Policy, Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA

PDB128
H6
INSULIN PUMPS FOR THE TREATMENT OF TYPE 1 DIABETES MELLITUS: WHY IS UPTAKE SO LOW IN THE UK?
Marsh WJ1, Kusel J2
1Costello Medical Consulting Ltd, Cambridge, UK, 2Costello Medical Consulting Ltd., Cambridge, UK

PDB129
H7
NEBIBE VAROL
Varol N1, Divino V2, Hallinan S2, Dekoven M2, Lee WC2, Reaney MD1
1Eli Lilly and Company, Windlesham, Surrey, UK, 2IMS Health, Alexandria, VA, USA

PDB130
H8
TREATMENT PATTERNS OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) AND LASER THERAPY AMONG PATIENTS WITH DIABETIC MACULAR EDEMA (DME)
Jiang S, Barner JC, Park C, Ling Y
The University of Texas at Austin, College of Pharmacy, Austin, TX, USA

PDB131
H9
UNITS AND COSTS PER DAY PER CLAIM OF COMPARABLE INSULINS SUPPLIED TO MEDICAID PATIENTS
Ivanova JI1, Foster S2, Desai U3, Hayes-Larson E1, King S3, Birnbaum HG3, Swindle R2
1Analysis Group, Inc., New York, NY, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Analysis Group, Inc., Boston, MA, USA

PDB132
H10
EXPENDITURE AND UTILIZATION TRENDS OF THE ANTIDIABETIC AGENTS IN QATAR (2007-2012)
Al-Badriyeh D1, Fares H1, Alokka M1, Fahey M2
1College of Pharmacy, Qatar University, Doha, Qatar, 2Hamad Medical Corporation, Doha, Qatar

PDB133
H11
TREND OF THE UTILIZATION AND COST OF PRESCRIPTION MEDICATIONS AMONG DIABETES PATIENTS IN THE U.S: 1987 TO 2010
Zhuo X
Centers for Disease Control and Prevention, Atlanta, GA, USA

PDB134
H12
THE IMPACT OF MEDICARE PART D ON DIABETES DRUG USE AND EXPENDITURES
Bonakdar Tehrani A
Virginia Commonwealth University, Richmond, VA, USA

PDB135
H13
CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF PEOPLE WITH TYPE 2 DIABETES MELLITUS (T2DM) INITIATING CANAGLIFLOZIN FROM A US MANAGED CARE SAMPLE
Martin S1, Henk H2, Chow W1
1Janssen Scientific Affairs, LLC, Raritan, NJ, USA, 2OptumInsight, Eden Prairie, MN, USA

PDB136
H14
MEDICATION USE AND TREATMENT PATTERNS OF GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST THERAPY IN TYPE 2 DIABETES MELLITUS
Johnston SS1, Nguyen H2, Felber E2, Cappell K1, Nelson J1, Chu B3, Kalsekar I2
1Truven Health Analytics, Bethesda, MD, USA, 2Bristol-Myers Squibb, Plainsboro, NJ, USA, 3Truven Health Analytics, Santa Barbara, CA, USA

PDB137
H15
REVIEW OF THE USUAL TREATMENT OF ADULTS WITH TYPE 2 DIABETES IN JAPAN
Katada A1, Ascher-Svanum H2
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Eli Lilly and Company, Indianapolis, IN, USA

PDB138
WITHDRAWN

PDB139
H16
UNDER-DIAGNOSIS OF TYPE II DIABETES AMONG CHILEAN ADULT MEN: AN URGENT EQUITY ISSUE
Cabieses B1, Willeke A1, Chepo M1, Espinoza MA2, Bernales M1
1Universidad del Desarrollo Clinica Alemana Chile, Santiago, Chile, 2Pontificia Universidad Católica de Chile, Santiago, Chile

PDB140
H17
OUT-OF-POCKET SPENDING AND FINANCIAL BURDEN OF PRESCRIPTION DRUGS FOR DIABETES: 2007-2010
Lu K, Yuan J, Wu J
South Carolina College of Pharmacy – USC Campus, Columbia, SC, USA

PDB141
H18
EXCESS HEALTHCARE EXPENDITURES ASSOCIATED WITH PRESENCE OF THYROID DISORDERS AMONG INDIVIDUALS WITH DIABETES: A COST-DECOMPOSITION ANALYSIS
Raval AD, Sambamoorthi U
West Virginia University, Morgantown, WV, USA

PDB142
WITHDRAWN

PDB143
H19
DISABILITY ADJUSTED LIFE YEARS LOST DUE TO DIABETES IN FRANCE, ITALY, GERMANY, SPAIN AND THE UNITED KINGDOM: A BURDEN OF ILLNESS STUDY
Darba J1, Kaskens L2, Detournay B3, Ramírez de Arellano A4
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics & Outcomes Research S.L., Barcelona, Spain, 3Cemka-Eval, Bourg la Reine, France, 4Novo Nordisk Pharma SA, Madrid, Spain

PDB144
H20
MATHEMATICAL SIMULATIONS OF ALOGLIPTIN-PIOGLITAZONE-TREATED PATIENTS MEETING QUALITY ASSURANCE HBA1C THRESHOLD REQUIREMENTS
Bilir SP1, Iversen P2, Bron-Green M3, Lee WC1
1IMS Health, San Francisco, CA, USA, 2IMS Health, London, CA, USA, 3Takeda, Deerfield, IL, USA

PDB145
H21
RELEVANCE OF CLINICAL TRIALS TO INFORM HTA: DISPARITY BETWEEN HTA EVIDENCE REQUIREMENTS AND PUBLISHED RCTS IN TYPE 2 DIABTETES MELLITUS
King DT1, Trautmann M2, Sabater J3, Pahor A4, Shaw JW5, Grandy S6, Budd D3, Mitchell SA1
1Abacus International, Bicester, UK, 2Diabetes Research, Hamburg, Germany, 3Bristol-Myers Squibb EMEA SARL, Paris, France, 4Astra Zeneca GmbH, Wedel, Germany, 5Bristol-Myers Squibb, Princeton, NJ, USA, 6AstraZeneca LP, Wilmington, DE, USA

PDB146
I1
PATIENT AWARENESS OF HBA1C IN TYPE 2 DIABETES: TRENDS AND IMPLICATIONS FOR HEALTH OUTCOMES
Annunziata K1, DiBonaventura M2, Sternbach N2
1Kantar Health, Princeton, NJ, USA, 2Kantar Health, New York, NY, USA

PDB147
I2
WHY PHYSICIANS DO NOT FOLLOW AACE/ACE GUIDELINES IN TREATING QUALIFIED PATIENTS WITH T2DM: A SURVEY STUDY IN THE UNITED STATES
Qiu Y1, Li Q1, Tang J2, Fan CS2, Li Z2, Apecechea de Scheffer M3, Hegar R3, Shankar R1, Engel SS1
1Merck Sharp & Dohme Corp., Whitehouse Station, NJ, USA, 2AscelpiusAnalytics Ltd., Hong Kong, Hong Kong, 3Kantar Health Germany, Munich, Germany

PDB148
I3
LONGITUDINAL PATTERNS OF ANTIDIABETES MEDICATION PRESCRIPTION AMONG PRIVATELY INSURED MEDICARE PATIENTS
Bae JP, Peng X, Jiang D, Zagar A
Eli Lilly and Company, Indianapolis, IN, USA

PDB149
I4
MEDICATION ADHERENCE AND SWITCHING RATES OF PATIENTS WITH TESTOSTERONE REPLACEMENT THERAPY (TRT) IN THE US
Puenpatom RA, Ma L, Camper SB
Endo Pharmaceuticals Inc., Malvern, PA, USA

PDB150
I5
PATTERNS OF MEDICATION USE IN THE ONE YEAR FOLLOWING INITIATION OF DPP-4 INHIBITORS IN THE US
Radawski C, Nelson DR, Nyhuis A, Mitchell B, Johnston JA
Eli Lilly and Company, Indianapolis, IN, USA

PDB151
I6
EVALUATION OF ASSOCIATION BETWEEN DIABETES RELATED QUALITY MEASURE ACHIEVEMENT AND DIABETES COMPLICATIONS IN A MEDICARE ADVANTAGE POPULATION
Ellis JJ1, Bouchard JR2, Saundankar V1, Moll K1, Baltz J3, Meah Y3, Moretz C1
1Comprehensive Health Insights, Louisville, KY, USA, 2Novo Nordisk Inc., Plainsboro, NJ, USA, 3Humana Inc., Louisville, KY, USA

PDB152
I7
A REGULATORY COMPARARISON OF NON-INSULIN DEPENDENT TYPE II DIABETES DRUG APPROVALS IN THE UNITED STATES AND EUROPEAN UNION
Sanchez DP, Rubinstein J, Rubinstein E, Sliman R, Daniel K, Ho YS
Context Matters, Inc., New York, NY, USA

PDB153
I8
DELAYED TREATMENT MODIFICATIONS FOR PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM) WITH VERY POOR GLYCEMIC CONTROL
Schwab P1, Saundankar V1, Bouchard JR2, Moretz C1, Baltz J3
1Comprehensive Health Insights, Louisville, KY, USA, 2Novo Nordisk, Inc., Princeton, NJ, USA, 3Humana Inc., Louisville, KY, USA

PDB154
I9
COST IMPLICATIONS OF EARLY DISCONTINUATION AND RESTART OF INSULIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
Ascher-Svanum H1, Lage MJ2, Perez M1, Reaney MD3, Lorraine J4, Rodriguez A5, Treglia M2
1Eli Lilly and Company, Indianapolis, IN, USA, 2HealthMetrics Outcomes Research, Bonita Springs, FL, USA, 3Eli Lilly and Company, Windlesham, Surrey, UK, 4Eli Lilly Canada, Toronto, ON, Canada, 5Eli Lilly Spain, Madrid, Spain

PDB155
I10
NATIONAL PATTERNS IN PRESCRIPTION MEDICATION TREATMENT FOR DIABETES: 2002-2010
Yuan J, Lu K, Wu J
South Carolina College of Pharmacy – USC Campus, Columbia, SC, USA

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.